RxDoctor Payments DataLook up a doctor →

Jorge Gonzalez, MD

Neurology · Tulsa, OKNPI 1073567392

Payments from drug & device makers

$18,771in general payments, 2019–2025

Across 879 payments — averaging $21.36 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Livanova USA, Inc.$2K
  • Sanofi$1K
  • Teva Pharmaceuticals USA, Inc.$1K
  • SK Life Science, Inc.$1K
  • UCB, Inc.$1K
  • AbbVie$967
  • plus $11K from 54 others

What the payments were for

  • Travel & lodging$1,2927%
  • Food & beverage$17,01591%
  • Education$4642%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Livanova USA, Inc.30$1,896
Sanofi45$1,231
Teva Pharmaceuticals USA, Inc.55$1,204
SK Life Science, Inc.46$1,144
UCB, Inc.54$1,024
AbbVie(2 entities)70$967
Medtronic(2 entities)11$908
Lilly USA, LLC51$885
Amgen(2 entities)64$776
Supernus Pharmaceuticals, Inc.51$635
Lundbeck LLC29$623
AstraZeneca21$539
Biogen25$537
Eisai Inc.21$506
Kyowa Kirin, Inc.22$428
Amneal Pharmaceuticals LLC15$375
EMD Serono, Inc.16$349
Biohaven Pharmaceutical Holding Company Ltd.22$318
Avanir Pharmaceuticals, Inc.23$289
Genentech USA, Inc.14$287
Biohaven Pharmaceuticals, Inc.10$249
Argenx US, Inc.11$236
Neurocrine Biosciences, Inc.10$231
Neurelis, Inc.10$230
Adamas Pharmaceuticals, Inc.12$209
Upsher-smith Laboratories LLC9$189
Corium, LLC9$184
CSL Behring4$174
Impel Pharmaceuticals Inc.9$172
Pfizer13$166
Novartis10$163
Arbor Pharmaceuticals, Inc.7$113
Merz Pharmaceuticals, LLC6$104
Johnson & Johnson5$102
Avion Pharmaceuticals5$96
Sanofi-aventis U.S. LLC1$91
Abbott4$87
Acadia Pharmaceuticals Inc5$86
Mallinckrodt Enterprises LLC4$82
Bristol Myers Squibb5$74
Catalyst Pharmaceuticals, Inc.3$72
Grifols USA, LLC4$69
Currax Pharmaceuticals LLC5$67
MDD US Operations, LLC3$56
Merz North America, Inc.3$53
GRT US Holding, Inc.3$51
Tanabe Pharma America, Inc.2$48
E.r. Squibb & Sons, L.L.C.3$48
ANI Pharmaceuticals, Inc.2$46
Otsuka America Pharmaceutical, Inc.2$44
Mallinckrodt Hospital Products Inc.2$37
Jazz Pharmaceuticals Inc.2$37
Azurity Pharmaceuticals, Inc.2$36
Sumitomo Pharma America, Inc.2$30
Neuronetics, Inc.1$25
Promius Pharma LLC1$18
Scilex Pharmaceuticals Inc.1$16
Tersera Therapeutics LLC1$16
Cala Health, Inc.1$15
Almatica Pharma LLC1$14

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$18,771 in reported general payments places this provider in the 75th percentile of 152 neurology providers in Oklahoma.

See all neurology providers in Oklahoma

Medicare billing

Part B allowed, 2024
$27,002
Medicare patients
248
Services billed
276

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VyvgartEfgartigimod Alfa-Fcab24$465,061
XcopriCenobamate45$67,826
AptiomEslicarbazepine Acetate11$27,077
Oxtellar XrOxcarbazepine18$23,803
Nurtec OdtRimegepant Sulfate12$17,734
Lacosamide54$11,070
Aimovig AutoinjectorErenumab-Aooe12$8,550
Dalfampridine ErDalfampridine21$7,635
Modafinil15$7,247
SavellaMilnacipran Hcl11$5,190
Carbidopa-Levodopa-EntacaponeCarbidopa/Levodopa/Entacapone29$4,348
Memantine Hcl165$3,544
AmantadineAmantadine Hcl84$2,909
Methazolamide28$2,486
Carbidopa-LevodopaCarbidopa/Levodopa165$2,153

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Argenx US, Inc.Vyvgart$236$465,06124 claims
SK Life Science, Inc.Xcopri$1,144$67,82645 claims
Supernus Pharmaceuticals, Inc.Oxtellar Xr$635$23,80318 claims
PfizerNurtec Odt$166$17,73412 claims
AbbVieSavella$967$5,19011 claims
Upsher-smith Laboratories LLCTopiramate$189$1,623133 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 152 neurology providers in Oklahoma.

Other neurology in Tulsa

See the full list for Oklahoma

Where these figures come from

Is this you, or does something look wrong? →